Menu
Back to User profile » Dr Hazem Abdulelah
Papers published by Dr Hazem Abdulelah:
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A
Breast Cancer: Targets and Therapy 2023, 15:1-10
Published Date: 13 January 2023
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H
Cancer Management and Research 2022, 14:1033-1041
Published Date: 8 March 2022
Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country
Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D
Cancer Management and Research 2019, 11:9891-9897
Published Date: 22 November 2019
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Al-Haj Ali B, Ibrahim M, Rimawi D
OncoTargets and Therapy 2018, 11:2091-2096
Published Date: 11 April 2018
Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study
Abdel-Razeq H, Abbasi S, Saadi I, Jaber R , Abdulelah H
Drug Design, Development and Therapy 2013, 7:939-944
Published Date: 30 August 2013